These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Antigen-specific inhibition of experimental autoimmune uveoretinitis by bone marrow-derived immature dendritic cells. Jiang HR; Muckersie E; Robertson M; Forrester JV Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1598-607. PubMed ID: 12657598 [TBL] [Abstract][Full Text] [Related]
8. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Keino H; Kezuka T; Takeuchi M; Yamakawa N; Hattori T; Usui M Arch Ophthalmol; 2004 Aug; 122(8):1179-84. PubMed ID: 15302659 [TBL] [Abstract][Full Text] [Related]
9. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan. Okunuki Y; Usui Y; Nagai N; Kezuka T; Ishida S; Takeuchi M; Goto H Invest Ophthalmol Vis Sci; 2009 May; 50(5):2255-61. PubMed ID: 19136706 [TBL] [Abstract][Full Text] [Related]
10. Amelioration of experimental autoimmune uveoretinitis by pretreatment with a pathogenic peptide in liposome and anti-CD40 ligand monoclonal antibody. Namba K; Ogasawara K; Kitaichi N; Morohashi T; Sasamoto Y; Kotake S; Matsuda H; Iwabuchi K; Iwabuchi C; Ohno S; Onoé K J Immunol; 2000 Sep; 165(6):2962-9. PubMed ID: 10975803 [TBL] [Abstract][Full Text] [Related]
11. Peptide-mediated suppression of experimental autoimmune uveoretinitis in mice: development of a peptide vaccine. Kezuka T; Sakai J; Yokoi H; Takeuchi M; Okada A; Taguchi O; Usui M; Mizuguchi J Int Immunol; 1996 Aug; 8(8):1229-35. PubMed ID: 8918692 [TBL] [Abstract][Full Text] [Related]
12. Orally induced bystander suppression in experimental autoimmune uveoretinitis occurs only in the periphery and not in the eye. Wildner G; Thurau SR Eur J Immunol; 1995 May; 25(5):1292-7. PubMed ID: 7774632 [TBL] [Abstract][Full Text] [Related]
13. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831 [TBL] [Abstract][Full Text] [Related]
14. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response. Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359 [TBL] [Abstract][Full Text] [Related]
15. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. De Kozak Y; Thillaye-Goldenberg B; Naud MC; Da Costa AV; Auriault C; Verwaerde C Clin Exp Immunol; 2002 Nov; 130(2):212-23. PubMed ID: 12390308 [TBL] [Abstract][Full Text] [Related]